A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2012
At a glance
- Drugs Erlotinib; Tivantinib
- Indications Solid tumours
- Focus Adverse reactions
- 11 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Additional lead investigators (Just RG, Rosen L) as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.